Analysis of circulating immunocytes of peripheral blood
PD
Circulating immunocytes, such as MDSCs, CD 4 T‐cells, CD8 T‐cells, and Tregs, were analyzed. To analyze circulating immunocytes, peripheral blood samples were collected in ten patients. Eight of the ten patients were from the PBgroup and two of the ten patients were from the Pgroup. The eight patients in the PBgroup were divided into two groups of four each. One group was the poor PFS group, and the other group was the good PFS group. In the poor PFS group, two patients had received induction therapy only, and two patients had received less than two cycles of maintenance therapy consisting of pemetrexed and bevacizumab. The reason for discontinuation of therapy in these four patients was PD. In the good PFS group, all four patients had received induction therapy and more than eight cycles of maintenance therapy, also consisting of pemetrexed and bevacizumab. Pretreatment M‐MDSC counts of peripheral blood of the patients are shown in Figure Pretreatment monocytic‐myeloid derived suppressor cell (M‐MDSC) counts of patients in the pemetrexed plus bevacizumab group by progression‐free survival (PFS). Counts tend to be greater in patients with poor PFS than in those with good PFS (